-
1 Comment
AFT Pharmaceuticals Limited is currently in a long term downtrend where the price is trading 3.6% below its 200 day moving average.
From a valuation standpoint, the stock is 98.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.5.
AFT Pharmaceuticals Limited's total revenue rose by 4.0% to $49M since the same quarter in the previous year.
Its net income has dropped by 88.0% to $1M since the same quarter in the previous year.
Finally, its free cash flow fell by 141.2% to $-1M since the same quarter in the previous year.
Based on the above factors, AFT Pharmaceuticals Limited gets an overall score of 2/5.
| Industry | Drug Manufacturers-Specialty & Generic |
|---|---|
| Sector | Healthcare |
| ISIN | NZAFTE0001S4 |
| CurrencyCode | AUD |
| Exchange | AU |
| Dividend Yield | 0.0% |
|---|---|
| Target Price | None |
| Beta | 0.27 |
| PE Ratio | 21.23 |
| Market Cap | 336M |
AFT Pharmaceuticals Limited develops, licenses, distributes, and sells pharmaceutical products in New Zealand, Australia, Asia, and internationally. It offers products for use in the areas of allergy, cold and flu, eyecare, first aid, pain management, gastrointestinal, dermatology, and medicated vitamins. The company was incorporated in 1997 and is headquartered in Auckland, New Zealand.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for AFP.AU using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
